Show simple item record

dc.contributor.authorValenciano, Marta
dc.contributor.authorKissling, Esther
dc.contributor.authorReuss, Annicka
dc.contributor.authorJiménez-Jorge, Silvia
dc.contributor.authorHorváth, Judit K
dc.contributor.authorDonnell, Joan M O
dc.contributor.authorPitigoi, Daniela
dc.contributor.authorMachado, Ausenda
dc.contributor.authorPozo, Francisco 
dc.date.accessioned2020-11-26T09:10:04Z
dc.date.available2020-11-26T09:10:04Z
dc.date.issued2015-06-04
dc.identifier.citationVaccine . 2015 Jun 4;33(24):2813-22.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11439
dc.description.abstractIn the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013-2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013-2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season. Practitioners systematically selected ILI patients to swab within eight days of symptom onset. We compared cases (ILI positive to influenza A(H3N2) or A(H1N1)pdm09) to influenza negative patients. We calculated VE for the two influenza A subtypes and adjusted for potential confounders. We calculated heterogeneity between sites using the I(2) index and Cochrane's Q test. If the I(2) was <50%, we estimated pooled VE as (1 minus the OR)×100 using a one-stage model with study site as a fixed effect. If the I(2) was >49% we used a two-stage random effects model. We included in the A(H1N1)pdm09 analysis 531 cases and 1712 controls and in the A(H3N2) analysis 623 cases and 1920 controls. For A(H1N1)pdm09, the Q test (p=0.695) and the I(2) index (0%) suggested no heterogeneity of adjusted VE between study sites. Using a one-stage model, the overall pooled adjusted VE against influenza A(H1N1)pdm2009 was 47.5% (95% CI: 16.4-67.0). For A(H3N2), the I(2) was 51.5% (p=0.067). Using a two-stage model for the pooled analysis, the adjusted VE against A(H3N2) was 29.7 (95% CI: -34.4-63.2). The results suggest a moderate 2013-2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectInfluenza vaccinees_ES
dc.subjectInfluenza vaccine effectivenesses_ES
dc.subjectMulticentre studyes_ES
dc.subjectTest-negative designes_ES
dc.subjectVaccine effectivenesses_ES
dc.subject.meshVaccine Potency es_ES
dc.subject.meshAdolescent es_ES
dc.subject.meshAdult es_ES
dc.subject.meshAged es_ES
dc.subject.meshCase-Control Studies es_ES
dc.subject.meshChild es_ES
dc.subject.meshChild, Preschool es_ES
dc.subject.meshEurope es_ES
dc.subject.meshEuropean Union es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInfant es_ES
dc.subject.meshInfant, Newborn es_ES
dc.subject.meshInfluenza A Virus, H1N1 Subtype es_ES
dc.subject.meshInfluenza A Virus, H3N2 Subtype es_ES
dc.subject.meshInfluenza Vaccines es_ES
dc.subject.meshInfluenza, Humanes_ES
dc.subject.meshMale es_ES
dc.subject.meshMiddle Aged es_ES
dc.subject.meshOdds Ratio es_ES
dc.subject.meshSeasons es_ES
dc.subject.meshSentinel Surveillance es_ES
dc.subject.meshTime Factors es_ES
dc.subject.meshVaccination es_ES
dc.titleThe European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2).es_ES
dc.typeArtículoes_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID25936723es_ES
dc.format.volume33es_ES
dc.format.number24es_ES
dc.format.page2813-22es_ES
dc.identifier.doi10.1016/j.vaccine.2015.04.012es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1873-2518
dc.relation.publisherversionhttps://doi.org/10.1016/j.vaccine.2015.04.012es_ES
dc.identifier.journalVaccinees_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional